本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场
审批编码：PP-IX-CN-4849
获批日期：2024 年 11 月 4 日
内容策划：杨娜
项目审核：曹欢
题图来源：丁香园设计
参考文献
[1] Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016 Mar;308(2):69-78.
[2] Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021 Jun;184(6):1047-1058.
[3] Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498.
[4] 依奇珠单抗说明书
[5] Chiricozzi A, Megna M, Giunta A, et al. Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study). J Dermatolog Treat. 2023 Dec;34(1):2246606.
[6] Valenti M, Gargiulo L, Ibba L, et al. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis). Dermatol Ther (Heidelb). 2024 Jun;14(6):1649-1657.
[7] Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2087-2100.
[8] Pinter A, Costanzo A, Khattri S, et al. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). Dermatol Ther (Heidelb). 2024 Jun;14(6):1479-1493.
[9] Ying L, Suyun J, Yanhua L, et al. Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study. Adv Ther. 2023 Dec;40(12):5464-5474.
[10] Ning Yu.Comprehensive analysis of effectiveness and cost-effectiveness of treatments for psoriasis integrating clinician- and patient-reported outcomes: a cohort study from SPEECH.
[11] Christopher E. M Griffiths, Melinda Gooderham, Jean-Frederic Colombel, et al. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. AAD 2022. 32236.
[12] Romiti R, Valenzuela F, Chouela EN, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol. 2019 Jul;181(1):202-203.
[13] Ying L, Suyun J, Yanhua L, et al. Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study. Adv Ther. 2023 Dec;40(12):5464-5474.
[14] Pinter A, et al. Association Between Disease Duration and Treatment Response in Patients With Moderate-to-Severe Plaque Psoriasis Treated With Biologics in a Real-world Setting: Results at Week 12 From the Psoriasis Study of Health Outcomes (PSoHO). EADV 2023. P2525.
[15] Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO). Front Med (Lausanne). 2023 Jun 29;10:1185523.
